Mynewsdesk

multippel sklerose Se alt tilgjengelig materiale for dette nøkkelordet

Pressemeldinger Se alle 7 treff

BIOGEN IDEC’S TECFIDERA™ (DIMETHYL FUMARATE) APPROVED IN US AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS

BIOGEN IDEC’S TECFIDERA™ (DIMETHYL FUMARATE) APPROVED IN US AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS

Pressemeldinger   •   03-04-2013 11:24

Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - - Reduces Relapses and Disability Progression - - Strengthens Biogen Idec’s Portfolio of Innovative Treatments for People Living with MS -

BIOGEN IDEC SØKER MARKEDSFØRINGSTILLATELSE FOR BG-12 I USA

BIOGEN IDEC SØKER MARKEDSFØRINGSTILLATELSE FOR BG-12 I USA

Pressemeldinger   •   29-02-2012 10:43

Biogen Idec har søkt såkalt New Drug Application (NDA) hos FDA (USA) for sitt nye orale legemiddel mot multippel sklerose (MS).

You haven't completed the steps for your Hosted Newsroom

You haven't entered a correct link to your helper.html file for your Hosted Newsroom. Go to Publish and complete the steps.